You are here: Home » Companies » News
Business Standard

Alembic Pharma arm gets tentative USFDA nod for drug to treat hypertension

Alembic Pharmaceuticals said its subsidiary has received tentative approval from the US health regulator for Treprostinil injection indicated for the treatment of pulmonary arterial hypertension

Topics
Alembic Pharmaceuticals | USFDA

Press Trust of India  |  New Delhi 

Alembic Pharmaceuticals ups its US game plan, acquires Orit
Alembic Pharmaceuticals

Drug firm on Monday said its subsidiary has received tentative approval from the US health regulator for Treprostinil injection indicated for the treatment of pulmonary arterial hypertension.

The tentatively approved product is therapeutically equivalent to the reference listed drug product Remodulin injection of United Therapeutics Corp.

Alembic Global Holdings SA has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Treprostinil Injection in the strengths of 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), multiple-dose vials, said in a regulatory filing.

Quoting United Therapeutics Corporation's 2019 financial results, Alembic Pharma said Treprostinil injection has an estimated market size of USD 466.1 million for the 12 months ending December 2019.

Alembic now has a total of 131 ANDA approvals (113 final approvals and 18 tentative approvals) from the

Shares of were trading 1.55 per cent lower at Rs 913 apiece on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 07 2020. 12:12 IST
RECOMMENDED FOR YOU
.